Limits...
Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.

Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC - BMC Cancer (2012)

Bottom Line: Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation.No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65).In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m(2) (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan.

ABSTRACT

Background: Lung cancer in young patients (less or equal to 45 years) is uncommon and has clinical characteristics different from that in older patients. We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC).

Methods: From January 2000 to December 2009, we enrolled patients aged ≤45 years and diagnosed with stage IIIB or IV NSCLC. Their clinical data, including age, gender, performance status, histologic types, disease stages, laboratory data at diagnosis, treatment modalities, and survival were reviewed and analyzed. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI).

Results: A total of 144 patients with advanced NSCLC were included. Female patients were more prevalent (n = 74, 51.4%). Adenocarcinoma was the most common histologic type (n = 119, 82.6%) in both genders (male, n = 54, 77.1%; female, n = 65, 87.8%). Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation. No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65). In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m(2) (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

Conclusions: Low BMI, stage IV disease, anemia at diagnosis, and male gender were the negative prognostic factors for young patients with advanced NSCLC.

Show MeSH

Related in: MedlinePlus

a. Proportion of adenocarcinoma in different age groups.b. Proportion of squamous cell carcinoma in different age groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3420246&req=5

Figure 2: a. Proportion of adenocarcinoma in different age groups.b. Proportion of squamous cell carcinoma in different age groups.

Mentions: Adenocarcinoma was the most common histologic type (n = 119, 82.6%), followed by undifferentiated carcinoma (n = 16, 11.1%) and squamous cell carcinoma (n = 9, 6.3%). There were no differences in the proportion of adenocarcinoma between genders (female vs. male, 87.8% vs. 77.1%, p = 0.12). Compare to other age groups (46–55, 56–65, 66–75, and 76 years or older) on the registry database of the National Taiwan University Hospital, younger patients (≤45 years) of both genders had the highest proportion of adenocarcinoma, and young males had the lowest proportion of squamous cell carcinoma (Figure 2a and 2b). Regarding disease stage, 40 patients (27.8%) had stage IIIB disease and 104 (72.2%) had stage IV disease. There were no significant differences between male and female patients in stage distribution.


Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.

Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC - BMC Cancer (2012)

a. Proportion of adenocarcinoma in different age groups.b. Proportion of squamous cell carcinoma in different age groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3420246&req=5

Figure 2: a. Proportion of adenocarcinoma in different age groups.b. Proportion of squamous cell carcinoma in different age groups.
Mentions: Adenocarcinoma was the most common histologic type (n = 119, 82.6%), followed by undifferentiated carcinoma (n = 16, 11.1%) and squamous cell carcinoma (n = 9, 6.3%). There were no differences in the proportion of adenocarcinoma between genders (female vs. male, 87.8% vs. 77.1%, p = 0.12). Compare to other age groups (46–55, 56–65, 66–75, and 76 years or older) on the registry database of the National Taiwan University Hospital, younger patients (≤45 years) of both genders had the highest proportion of adenocarcinoma, and young males had the lowest proportion of squamous cell carcinoma (Figure 2a and 2b). Regarding disease stage, 40 patients (27.8%) had stage IIIB disease and 104 (72.2%) had stage IV disease. There were no significant differences between male and female patients in stage distribution.

Bottom Line: Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation.No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65).In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m(2) (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

View Article: PubMed Central - HTML - PubMed

Affiliation: Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan.

ABSTRACT

Background: Lung cancer in young patients (less or equal to 45 years) is uncommon and has clinical characteristics different from that in older patients. We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC).

Methods: From January 2000 to December 2009, we enrolled patients aged ≤45 years and diagnosed with stage IIIB or IV NSCLC. Their clinical data, including age, gender, performance status, histologic types, disease stages, laboratory data at diagnosis, treatment modalities, and survival were reviewed and analyzed. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI).

Results: A total of 144 patients with advanced NSCLC were included. Female patients were more prevalent (n = 74, 51.4%). Adenocarcinoma was the most common histologic type (n = 119, 82.6%) in both genders (male, n = 54, 77.1%; female, n = 65, 87.8%). Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation. No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65). In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m(2) (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

Conclusions: Low BMI, stage IV disease, anemia at diagnosis, and male gender were the negative prognostic factors for young patients with advanced NSCLC.

Show MeSH
Related in: MedlinePlus